Cointime

Dewpoint Therapeutics

company

About

Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates.

  • 101 - 250

Highlights

Total Funding Amount
$227M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Series C
Last Funding Money Raised
$150M
Industries
Biotechnology,Life Science,Medical,Therapeutics
Founded date
Jan 1, 2018
Number Of Employee
101 - 250
Operating Status
Active

Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates. Its technology uses machine-learning-based image analysis tools for visualizing condensates and offers an engine for genetically linked condensatopathy which is a collection of engineered cell lines with trackable condensates to prevent harmful protein sequestration, helping healthcare providers to have access to new therapies to address unmet needs.

The company was founded in 2018 and is headquartered in Boston, Massachusetts.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$227M
Dewpoint Therapeutics has raised a total of $227M in funding over 2 rounds. Their latest funding was raised on Feb 3, 2022 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 3, 2022 Series C $150M 2 — — Detail
Sep 29, 2020 Series B $77M 1 ARCH Venture Partners — Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Dewpoint Therapeutics is funded by 2 investors. General Catalyst and ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
General Catalyst — Series C
ARCH Venture Partners — Series C
Cointime
Chủ Đề
Công Ty